VEGFA and diabetic retinopathy: While intravitreal anti‐VEGF injection represents a major breakthrough for the treatment of retinal neovascular diseases, not all patients respond to anti‐VEGF agents (Ashraf et al., 2016; Ip et al., 2015; Writing Committee for the Diabetic Retinopathy Clinical Research et al., 2015).